|
Invitae Corporation (NYSE: NVTA) |
|
Invitae Corporation
NVTA's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Invitae's sales fell
by -9.21 % in III. Quarter 2023 from the same quarter a year ago.
Ranking at No. 2841
Medical Laboratories industry recorded
growth of revenues by 4.32 %
Invitae net loss increased from $-301 millions, to $-942 millions in III. Quarter 2023,
• More on NVTA's Growth
|
|
Invitae realized a net loss in trailing twelve months.
Invitae realized cash reduction of $ -0.21 per share in trailing twelve-month period. |
Company |
-0 |
PE TTM
|
Industry |
-0 |
PE TTM
|
|
Company's Price to Sales ratio is at 0.01.
Medical Laboratories industry's Price to Sales ratio is at 2.1.
• More on NVTA's Valuation
|
|
|
|
|
Invitae realized net loss in trailing twelve months.
Invitae realized cash outflow of $ -0.21per share in trailing twelve-month period. |
Company |
-0 |
PE TTM
|
Industry |
-0 |
PE TTM
|
|
Company's Price to Sales ratio is at 0.01.
Medical Laboratories industry's Price to Sales ratio is at 2.1.
• More on NVTA's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com